National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
119
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

fertility reduction). That some population growth will result from infant and child mortality reduction highlights the need for integration of agricultural and health planning to avoid food shortages.

The method of ranking in this report uses an aggregate or global perspective, but the actual benefits from new vaccines will not be distributed evenly among regions, countries, socioeconomic groups, ethnic groups, age groups, or other population subsets. The committee’s method can provide useful information about the distribution of potential benefits, but the committee recommends that relevant equity issues should be addressed in a broader political/public policy forum. The portfolio approach could help focus the decision-making process.

The proposed system treats each vaccine development project independently, but some projects may have a wider impact. For example, a pertussis vaccine that caused fewer reactions might help increase public confidence in immunization programs in general and decrease failure to complete recommended schedules. Specific diseases may also interact synergistically in causing mortality. These interactions are difficult to quantify, but they should be considered by those setting vaccine priorities.

Other nonquantifiable factors that might affect project rankings include the availability of alternative measures of disease control or treatment, the potential impact of epidemic disease on health care facilities, and the opportunity for complete eradication of a particular disease.

In implementing the program of accelerated vaccine development, decision makers periodically should review activity in the private sector to identify projects for which public-private collaboration might expedite development, and to identify industry-scientific disincentives to the development of high-priority vaccines. Additional governmental funding for these vaccines (e.g., for clinical trials) might make them attractive to commercial manufacturers.

In the ultimate selection of a portfolio of candidates for accelerated vaccine development, information obtained from the analysis described in Chapters 3, 7, and 9 must be integrated with the nonquantifiable considerations discussed here.

REFERENCES

Ashworth, A., and R.G.Feachem. 1985. Interventions for the control of diarrheal diseases among young children: Prevention of low birthweight. Bull. WHO 63:165–186.


Bloom, B. 1985. Personal communication, Albert Einstein College of Medicine, Bronx, New York.

Bongaarts, J., and J.Menken. 1983. The supply of children: A critical essay. Pp. 27–60 in Determinants of Fertility in Developing Countries, Vol. 1, R.A.Bulatao and R.D.Lee, eds. New York: Academic.


Cochrane, S.H., and K.C.Zachariah. 1983. Infant and child mortality as determinants of fertility: The policy implications. World Bank Staff Working Papers, No. 556. Washington, D.C.

Page
119
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)